Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database
- PMID: 22250850
- DOI: 10.1111/j.1365-2516.2011.02739.x
Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database
Abstract
Neutralizing inhibitors develop in 20-30% of patients with severe factor VIII (FVIII) deficiency. It is well established that Blacks have a higher prevalence of inhibitors than Whites. This is the first study to definitively demonstrate increased inhibitor prevalence in the Hispanic population. We compared inhibitor prevalence among various racial and ethnic groups in a cross-sectional analysis of 5651 males with severe haemophilia A that participated in the Universal Data Collection project sponsored by the Centers for Disease Control and Prevention. We used logistic regression analysis to control for potential confounding variables. We assigned as Hispanic those participants who were white and labelled themselves Hispanic. The prevalence of high-titre inhibitors in the Hispanic participants was 24.5% compared to 16.4% for White non-Hispanic patients (OR 1.4, 95% CI 1.1, 1.7). Possibilities as to the underlying cause of increased inhibitor prevalence in minority ethnic populations include polymorphisms in the FVIII molecule, HLA subtypes and differing inflammatory responses. A better understanding may lead to tailored treatment programmes, or other therapies, to decrease or prevent inhibitor development.
© 2012 Blackwell Publishing Ltd.
Similar articles
-
Low prevalence of inhibitor antibodies in the Canadian haemophilia population.Haemophilia. 2012 May;18(3):e254-9. doi: 10.1111/j.1365-2516.2011.02694.x. Epub 2011 Nov 14. Haemophilia. 2012. PMID: 22077390
-
F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.Haemophilia. 2012 May;18(3):375-82. doi: 10.1111/j.1365-2516.2011.02700.x. Epub 2011 Nov 21. Haemophilia. 2012. PMID: 22103590
-
Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group.Thromb Haemost. 1992 Jun 1;67(6):600-2. Thromb Haemost. 1992. PMID: 1509398 Clinical Trial.
-
Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.Haematologica. 2001 Nov;86(11):1186-93. Haematologica. 2001. PMID: 11694405
-
The epidemiology of factor VIII inhibitors.Haemophilia. 2006 Dec;12 Suppl 6:23-8; discussion 28-9. doi: 10.1111/j.1365-2516.2006.01362.x. Haemophilia. 2006. PMID: 17123390 Review.
Cited by
-
Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.Blood Adv. 2024 Jun 11;8(11):2726-2739. doi: 10.1182/bloodadvances.2023011780. Blood Adv. 2024. PMID: 38564770 Free PMC article.
-
Variant spectrum of F8 and F9 in hemophilia patients from southern China and 26 novel variants.Front Genet. 2023 Dec 22;14:1254265. doi: 10.3389/fgene.2023.1254265. eCollection 2023. Front Genet. 2023. PMID: 38196513 Free PMC article.
-
Racial and ethnic differences in reported haemophilia death rates in the United States.Haemophilia. 2023 Nov;29(6):1410-1418. doi: 10.1111/hae.14859. Epub 2023 Sep 17. Haemophilia. 2023. PMID: 37718571 Free PMC article. Review.
-
Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors.Hematol Rep. 2023 Feb 16;15(1):130-150. doi: 10.3390/hematolrep15010014. Hematol Rep. 2023. PMID: 36810557 Free PMC article. Review.
-
Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?Blood Adv. 2023 Sep 12;7(17):4983-4998. doi: 10.1182/bloodadvances.2021004909. Blood Adv. 2023. PMID: 36459498 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials

